Across TCGA pan-cancer cohorts, KRTAP4-1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KRTAP4-1 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher KRTAP4-1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP4-1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, LIHC, and UCEC are the cancer types where KRTAP4-1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	48	view →
LIHC	DFS	Median	II,III,IV	0.114	0.429	.043	3	view →
UCEC	DFS	Median	All	1.000	0.630	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: KRTAP4-1 tumor-vs-normal RNA expression · all KRTAP4-1 data types